PP
WST icon

Postrock Partners’s West Pharmaceutical WST Stock Holding History

Postrock Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-771
Closed -$212K – 85
2025
Q4 		$212K Hold
771
– – 0.09% 80
2025
Q3 		$202K Buy
+771
New +$187K 0.09% 82
2025
Q1 		– Sell
-771
Closed -$253K – 86
2024
Q4 		$253K Buy
+771
New +$243K 0.12% 73

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Postrock Partners's WST Position: Q1 2026 in Review

Postrock Partners sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 771 shares — an estimated $212K sold.

Postrock Partners first reported a position in WST in Q4 2024 and held it in 3 quarters. The position peaked at $253K in Q4 2024. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Postrock Partners reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Postrock Partners sold 771 West Pharmaceutical shares in Q1 2026, an estimated $212K.
  • Postrock Partners first reported a position in West Pharmaceutical in Q4 2024 and held it in 3 quarters.
  • Postrock Partners's West Pharmaceutical position peaked at $253K in Q4 2024.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Postrock Partners's 13F filing for Q1 2026, filed 6 May 2026.